CN102970868A - 具有k-ras突变的癌症的治疗 - Google Patents

具有k-ras突变的癌症的治疗 Download PDF

Info

Publication number
CN102970868A
CN102970868A CN2011800290564A CN201180029056A CN102970868A CN 102970868 A CN102970868 A CN 102970868A CN 2011800290564 A CN2011800290564 A CN 2011800290564A CN 201180029056 A CN201180029056 A CN 201180029056A CN 102970868 A CN102970868 A CN 102970868A
Authority
CN
China
Prior art keywords
aryl
alkyl
amino
compound
iso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800290564A
Other languages
English (en)
Chinese (zh)
Inventor
鲁迪·宝
赖正荣
钱长庚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of CN102970868A publication Critical patent/CN102970868A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CN2011800290564A 2010-04-16 2011-04-15 具有k-ras突变的癌症的治疗 Pending CN102970868A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32491210P 2010-04-16 2010-04-16
US61/324,912 2010-04-16
PCT/US2011/032683 WO2011130628A1 (fr) 2010-04-16 2011-04-15 Traitement de cancers présentant des mutations k-ras

Publications (1)

Publication Number Publication Date
CN102970868A true CN102970868A (zh) 2013-03-13

Family

ID=44799046

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800290564A Pending CN102970868A (zh) 2010-04-16 2011-04-15 具有k-ras突变的癌症的治疗

Country Status (6)

Country Link
EP (1) EP2557923A4 (fr)
JP (1) JP2013525308A (fr)
CN (1) CN102970868A (fr)
AU (1) AU2011239537A1 (fr)
CA (1) CA2795952A1 (fr)
WO (1) WO2011130628A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103601745A (zh) * 2013-11-26 2014-02-26 大连联化化学有限公司 一种通用的乙酰氨基吡啶硼酸频哪醇酯的制备方法
WO2016169417A1 (fr) * 2015-04-21 2016-10-27 成都金瑞长青生物科技有限公司 Dérivés de purinyl-n-hydroxylpyrimidine-formamide, leur procédé de préparation et leur utilisation
CN106456643A (zh) * 2014-03-31 2017-02-22 斯克里普斯研究学院 用于trail诱导的药效团
CN110669047A (zh) * 2013-11-15 2020-01-10 昂克希尔迪克斯有限公司 用于治疗癌症的化合物、其组合物及应用方法
CN113735830A (zh) * 2021-10-11 2021-12-03 成都自豪药业有限公司 一类羟肟酸衍生物及其应用
WO2024041519A1 (fr) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 Composé morpholinyl quinazoline, composition pharmaceutique et utilisation associée

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032162A1 (fr) * 2006-09-15 2008-03-20 Pfizer Products Inc. Composés de pyrido (2, 3-d) pyrimidin0ne et leur utilisation en tant qu'inhibiteurs de pi3
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
LT3111938T (lt) 2011-04-01 2019-06-25 Curis, Inc. Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi
AU2012340869B2 (en) * 2011-11-23 2017-03-02 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase C
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9745321B2 (en) * 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
US9403779B2 (en) * 2013-10-08 2016-08-02 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
CN104131034B (zh) * 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
KR20170107536A (ko) * 2015-01-30 2017-09-25 바스프 에스이 제초 페닐피리미딘
CN105037345B (zh) * 2015-06-09 2019-01-25 天津渤海职业技术学院 抗肿瘤化合物、其制备方法和用途
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
EP3521290A4 (fr) * 2016-09-29 2020-04-22 Daiichi Sankyo Company, Limited Cristaux de [2-(1-méthyl-1h-pyrazol-4-yl)-6-(morpholin-4-yl)-9h-purin-8-yl][4-(morpholin-4-yl)pipéridin-1-yl]méthanone et sel pharmaceutiquement acceptable de celle-ci
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
CA3099148A1 (fr) * 2018-05-10 2019-11-14 The University Of Louisville Research Foundation, Inc. Inhibiteurs de l'oncoproteine ras, leurs procedes de preparation et leurs methodes d'utilisation
JP7467423B2 (ja) 2018-09-11 2024-04-15 キュリス，インコーポレイテッド 亜鉛結合部分を有するホスホイノシチド３－キナーゼ阻害剤との併用療法
US20230078755A1 (en) 2018-12-19 2023-03-16 Shy Therapeutics, Llc Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
EP3935050A4 (fr) 2019-03-06 2023-01-04 C4 Therapeutics, Inc. Composés hétérocycliques pour traitement médical
CN115843272A (zh) 2020-05-08 2023-03-24 哈利亚治疗公司 Nek7激酶的抑制剂
JP2023529354A (ja) * 2020-06-04 2023-07-10 ピライ ユニバーサル エルエルシー 癌治療における標的化不能ｋｒａの標的分解のための新規の小分子

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101626758A (zh) * 2007-02-15 2010-01-13 诺瓦提斯公司 用于治疗癌症的lbh589和其他治疗剂的组合
CN101675053A (zh) * 2006-12-07 2010-03-17 健泰科生物技术公司 磷酸肌醇3-激酶抑制剂化合物及使用方法
CN102341108A (zh) * 2009-01-08 2012-02-01 柯瑞斯公司 具有锌结合半族的磷酸肌醇3-激酶抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1362675B (it) * 2005-03-15 2009-06-25 Menarini Internat Operations Luxembourg Sa N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
WO2008076447A2 (fr) * 2006-12-15 2008-06-26 Ordway Research Institute Traitements de maladies résistantes aux thérapies et combinaisons médicamenteuses pour traiter celles-ci
US8466193B2 (en) * 2008-04-15 2013-06-18 Pharmacyclics, Inc. Selective inhibitors of histone deacetylase
WO2009155659A1 (fr) * 2008-06-27 2009-12-30 The University Of Queensland Polythérapie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101675053A (zh) * 2006-12-07 2010-03-17 健泰科生物技术公司 磷酸肌醇3-激酶抑制剂化合物及使用方法
CN101626758A (zh) * 2007-02-15 2010-01-13 诺瓦提斯公司 用于治疗癌症的lbh589和其他治疗剂的组合
CN102341108A (zh) * 2009-01-08 2012-02-01 柯瑞斯公司 具有锌结合半族的磷酸肌醇3-激酶抑制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENNIS WEGENER ET AL: "Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay", 《BIOCHEM.J.》, vol. 413, 31 December 2008 (2008-12-31) *
JEFFREY A.ENGELMAN: "targeting PI3K signalling in cancer：opportunities，challenges and limitations", 《NATURE REVIEWS CANCER》, vol. 9, 31 August 2009 (2009-08-31), XP002693047, DOI: doi:10.1038/NRC.2664 *
SHIN-ICHI YAGUCHI ET AL: "Antitumor activity of ZSTK474,a new phosphatidylinositol 3-kinase inhibitor", 《JOURNAL OF THE NATIONAL CANCER INSTITUTE》, vol. 98, no. 8, 19 April 2006 (2006-04-19), XP008149295, DOI: doi:10.1093/jnci/djj133 *
无: "curis presents preclinical data for CU-903 at keystone symposia event "PI3 kinase signaling in disease"", 《HTTP://WWW.DRUGS.COM/CLINICAL_TRIALS/CURIS-PESENTS-PRECLINICAL-DATA-CU-903-KEYSTONE-SYMPOSIA-EVENT-8220-PI3-KINASE-SIGNALING-8221-7094.HTML#0_UNDEFINED,0_》, 30 April 2009 (2009-04-30) *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110669047A (zh) * 2013-11-15 2020-01-10 昂克希尔迪克斯有限公司 用于治疗癌症的化合物、其组合物及应用方法
CN103601745A (zh) * 2013-11-26 2014-02-26 大连联化化学有限公司 一种通用的乙酰氨基吡啶硼酸频哪醇酯的制备方法
CN111499636B (zh) * 2014-03-31 2023-01-13 斯克里普斯研究学院 用于trail诱导的药效团
US10633385B2 (en) 2014-03-31 2020-04-28 The Scripps Research Institute Pharmacophore for trail induction
US11891392B2 (en) 2014-03-31 2024-02-06 The Scripps Research Institute Pharmacophore for trail induction
US10239877B2 (en) 2014-03-31 2019-03-26 The Scripps Research Institute Pharmacophore for trail induction
CN111499636A (zh) * 2014-03-31 2020-08-07 斯克里普斯研究学院 用于trail诱导的药效团
CN106456643A (zh) * 2014-03-31 2017-02-22 斯克里普斯研究学院 用于trail诱导的药效团
CN106456643B (zh) * 2014-03-31 2020-04-17 斯克里普斯研究学院 用于trail诱导的药效团
EA033106B1 (ru) * 2015-04-21 2019-08-30 Гуйчжоу Бэйлинг Груп Фармасьютикал Ко., Лтд. Производное пуринил-n-гидроксипиримидинформамида, способы его получения и его применения
AU2016250972B2 (en) * 2015-04-21 2019-01-17 Chengdu Zenitar Biomedical Technology Co., Ltd. Purinyl-n-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
WO2016169417A1 (fr) * 2015-04-21 2016-10-27 成都金瑞长青生物科技有限公司 Dérivés de purinyl-n-hydroxylpyrimidine-formamide, leur procédé de préparation et leur utilisation
US10227347B2 (en) 2015-04-21 2019-03-12 Guizhou Bailing Group Pharmaceutical Co., Ltd. Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
CN113735830A (zh) * 2021-10-11 2021-12-03 成都自豪药业有限公司 一类羟肟酸衍生物及其应用
WO2023061368A1 (fr) * 2021-10-11 2023-04-20 成都自豪药业有限公司 Dérivé d'acide hydroximique et son utilisation
WO2024041519A1 (fr) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 Composé morpholinyl quinazoline, composition pharmaceutique et utilisation associée

Also Published As

Publication number Publication date
CA2795952A1 (fr) 2011-10-20
EP2557923A1 (fr) 2013-02-20
AU2011239537A1 (en) 2012-11-15
EP2557923A4 (fr) 2013-10-23
WO2011130628A1 (fr) 2011-10-20
JP2013525308A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
CN102970868A (zh) 具有k-ras突变的癌症的治疗
CN102341108B (zh) 具有锌结合半族的磷酸肌醇3-激酶抑制剂
CN101959404B (zh) 单磷酸腺苷活化蛋白激酶调节剂
CN101573333B (zh) 组蛋白脱乙酰酶抑制剂
US20230372496A1 (en) Tricyclic heterobifunctional compounds for degradation of targeted proteins
CN105026398B (zh) 用于治疗疾病诸如癌症的***并[4,5-d]嘧啶衍生物
CN102574842B (zh) 用于抑制pi3激酶的吡啶基咪唑酮衍生物
CN104203242B (zh) 取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂
CN106456609A (zh) 作为irak4抑制剂的取代的吲唑化合物
CN104395315A (zh) 作为LRRK2抑制剂的新的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
CN101790527A (zh) Rho激酶的苯并噻吩抑制剂
US20130102595A1 (en) Treatment of cancers having k-ras mutations
CN107108637A (zh) ***并嘧啶化合物及其用途
JP6912039B2 (ja) 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用
CN105051041A (zh) 杂环谷氨酰胺酶抑制剂
JP2016519660A (ja) ブロモドメイン阻害剤としてのオキサゾロ［５，４−ｃ］キノリン−２−オン化合物
CN104606194A (zh) Pde4的双环杂芳基抑制剂
MX2014007230A (es) Derivados de tieno [3,2 - d]pirimidina que tienen actividad inhibidora de las cinasas de proteina.
CN103159742A (zh) 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
CN101100472A (zh) 4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用
CN105793262B (zh) 二环炔衍生物及其用途
CN104066734B (zh) ***并[4,5‑d]嘧啶衍生物
EP2896620A1 (fr) Composé cyclique hétéroaromatique alcynylique et son application
CN110291089A (zh) 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
CN107056755B (zh) 五元杂环酰胺类wnt通路抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130313